were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks.

The 40-week trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes ...

Back to Healio SAN FRANCISCO — A 1.5 mg daily dose of dulaglutide may limit kidney function deterioration and the onset of end-stage renal disease for adults with type 2 diabetes and chronic ...

For participants who were randomly assigned to receive the 1.5-mg dose, dulaglutide was initiated at the 0.75-mg dose for the first 4 weeks and then escalated to the 1.5-mg dose if the participant ...

Participants were randomly assigned to subcutaneous semaglutide 0.5 mg (n = 301; mean age, 56 years; 56% men; 77% white; mean HbA1c, 8.3%; mean diabetes duration, 7.7 years), dulaglutide 0.75 mg ...

AWARD-2: Once-Weekly Dulaglutide 0.75 mg Non-Inferior, 1.5 mg Superior in HbA1c Reduction from Baseline with Sustained Weight Loss and Lower Risk for Hypoglycemia "Many patients with type 2 ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial ...

showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c ...

0.6% drop 1.5-mg group: -0.9% drop Placebo: 0.6% increase As for fasting glucose levels, these increased by 17.1 mg/dL for youth on placebo but dropped by 18.9 mg/dL among all kids on dulaglutide.

The initial dose is 0.75 mg once a week. The dose can be increased to 1.5 mg for further lowering of blood glucose. Dulaglutide is a glucagon-like peptide 1 (GLP-1) agonist used as an additional ...

Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks. The primary endpoint was the change in HbA1c from baseline to week 28. Superiority of ...